Citi lowered the firm’s price target on Pulmonx (LUNG) to $4.15 from $6.50 and keeps a Neutral rating on the shares. The firm updated models in medical technology following the Q1 reports. The good news is that underlying sector fundamentals appear intact, including volumes, pricing, and capex, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LUNG:
- Pulmonx Corporation’s Earnings Call Highlights Growth and Challenges
- Pulmonx price target lowered to $9 from $10 at Piper Sandler
- Pulmonx price target lowered to $15 from $16 at Canaccord
- Pulmonx Positioned for Sustained Growth with Strong Q1 Performance and Strategic Initiatives
- Pulmonx Corporation Reports Strong Q1 2025 Results